← Back to Home

Annamycin Combined with Immunotherapy Extends Survival in Mice with Pancreatic Cancer, with T Cells Emerging as a Key Clue

Moleculin released animal study results showing that Annamycin combined with PD-1 blockade extended survival more than either treatment alone. The findings offer a research direction for pancreatic cancer immunotherapy, but there is no evidence of efficacy in humans, and a planned clinical trial also faces a funding gap.

By SURL BioNews

For immunotherapy to work, tumors must first contain immune cells capable of mounting a response. Pancreatic cancer often lacks this condition, limiting the effectiveness of immune checkpoint inhibitors. On November 10, Moleculin Biotech announced findings from mouse studies: the investigational drug Annamycin combined with PD-1 blockade extended survival more effectively than either treatment alone, providing new clues for altering the immune environment in pancreatic cancer.

According to the company’s announcement, the research used an immunocompetent syngeneic KPC mouse model to simulate advanced pancreatic ductal adenocarcinoma. Liposomal Annamycin combined with PD-1 blockade produced significantly longer survival than either single-agent treatment; a second independent experiment reproduced the result. However, the announcement did not provide the number of animals in each group, median survival, or complete statistical data, leaving readers unable to assess the magnitude of the benefit or the robustness of the findings.

Changes in immune cells were an important part of the study. Tumors treated with Annamycin showed increased infiltration by CD8+ cytotoxic T cells and CD4+ helper T cells; when researchers further suppressed CD8+ cells, the animals’ survival shortened. This intervention supports the involvement of T cells in the antitumor effect, but does not fully explain how the drug brings about these changes.

Another clue concerns whether the drug can reach the pancreas. The company said that, at the same dose, Annamycin achieved higher exposure in pancreatic tissue than doxorubicin and persisted longer; tumors also showed DNA damage consistent with topoisomerase II activity. These observations offer directions for studying the connections between drug penetration into tissue, tumor damage, and immune cell involvement, but cannot directly establish that the same effects would occur in humans.

The new evidence lies in the survival results for the two-drug combination. According to the company, the team had already reported Annamycin’s activity in animal models of pancreatic cancer and the contribution of CD8+ cells in April and September of this year; the November announcement advanced the research to combination treatment with immune checkpoint blockade. The announcement also stated that Waldemar Priebe of MD Anderson Cancer Center had been scheduled to present the findings on November 10 at a symposium hosted by Moffitt Cancer Center.

The publicly available evidence still consists primarily of company disclosures. An exhibit filed with the U.S. Securities and Exchange Commission preserves the same announcement and does not constitute another independent study or scientific validation. Reproducing the results in a second experiment also does not mean that an external team has validated them; the combination’s safety, appropriate patient population, and survival benefit in human pancreatic cancer all remain unknown.

Moleculin said it plans to sponsor an investigator-initiated clinical trial of Annamycin in pancreatic cancer in 2027, but the announcement did not specify whether it would use this two-drug combination. The company also disclosed that conducting the described clinical trial would require substantial additional funding and that it had not secured financing commitments at the time. Moving from immune responses in mice to treatment for patients will next require both confirmation of the trial design and securing the funding and conditions needed to carry it out.

References

  1. The Manila Times
  2. Moleculin Biotech
  3. U.S. Securities and Exchange Commission — Moleculin Biotech exhibit